253 related articles for article (PubMed ID: 35575446)
1. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
Lehtinen AE; Baghaei F; Astermark J; Holme PA
Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
[TBL] [Abstract][Full Text] [Related]
2. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
[TBL] [Abstract][Full Text] [Related]
3. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
Wang C; Young G
Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
[TBL] [Abstract][Full Text] [Related]
4. Single centre, real-world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery.
O'Donovan M; Singleton E; Roche S; McGowan M; Benson J; Bergin C; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; Dougall A; O'Donnell JS; O'Connell NM
Haemophilia; 2021 Nov; 27(6):e690-e697. PubMed ID: 34614282
[TBL] [Abstract][Full Text] [Related]
5. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A.
Mahlangu JN; Ragni M; Gupta N; Rangarajan S; Klamroth R; Oldenburg J; Nogami K; Young G; Cristiano LM; Dong Y; Allen G; Pierce GF; Robinson B
Thromb Haemost; 2016 Jul; 116(1):1-8. PubMed ID: 26962852
[TBL] [Abstract][Full Text] [Related]
6. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
Haemophilia; 2021 Sep; 27(5):751-759. PubMed ID: 34160870
[TBL] [Abstract][Full Text] [Related]
7. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
Brennan Y; Parikh S; McRae S; Tran H
Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
[TBL] [Abstract][Full Text] [Related]
9. Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery.
Désage S; Nougier C; Meunier S; Chamouard V; Jousselme E; Dargaud Y; Lienhart A
Haemophilia; 2024 Mar; 30(2):538-544. PubMed ID: 38149726
[TBL] [Abstract][Full Text] [Related]
10. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
Shapiro A; Chaudhury A; Wang M; Escobar M; Tsao E; Barnowski C; Feng J; Jain N; Quon DV
Haemophilia; 2020 Nov; 26(6):975-983. PubMed ID: 33012060
[TBL] [Abstract][Full Text] [Related]
11. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
[TBL] [Abstract][Full Text] [Related]
12. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies.
Chowdary P; Holmström M; Mahlangu JN; Ozelo MC; Pabinger I; Pasi KJ; Ragni MV; Shapiro A; Barnowski C; Lethagen S
Res Pract Thromb Haemost; 2022 Jul; 6(5):e12760. PubMed ID: 35910942
[TBL] [Abstract][Full Text] [Related]
13. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
Pochopien M; Tytuła A; Toumi M; Falk A; Martone N; Hakimi Z; Eriksson D
Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
[TBL] [Abstract][Full Text] [Related]
15. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
[TBL] [Abstract][Full Text] [Related]
17. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.
Powell J; Shapiro A; Ragni M; Negrier C; Windyga J; Ozelo M; Pasi J; Baker R; Potts J; Li S; Mei B; Pierce GF; Robinson B
Br J Haematol; 2015 Jan; 168(1):113-23. PubMed ID: 25209873
[TBL] [Abstract][Full Text] [Related]
18. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
Oldenburg J; Hay CRM; Jiménez-Yuste V; Peyvandi F; Schved JF; Szamosi J; Winding B; Lethagen S
BMJ Open; 2019 May; 9(5):e028012. PubMed ID: 31152037
[TBL] [Abstract][Full Text] [Related]
19. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.
Wang M; Álvarez-Román MT; Chowdary P; Quon DV; Schafer K
Blood Coagul Fibrinolysis; 2016 Oct; 27(7):737-744. PubMed ID: 27116081
[TBL] [Abstract][Full Text] [Related]
20. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
